Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 15

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 15
---
 are unregistered warrants, to purchase up to an aggregate
of 1,500,000 Common Shares in the concurrent January 2024 Private Placement. The January 2024 PIPE Warrants are exercisable upon issuance
at an exercise price of $1.60 per common share, subject to adjustment as set forth therein, and have a 5-year term from the issuance date.
The January 2024 PIPE Warrants may be exercised on a cashless basis if at the time of exercise thereof, there is no effective registration
statement registering the Common Shares underlying the January 2024 PIPE Warrants. We paid the placement agent in the registered direct
offering and January 2024 Private Placement a cash placement fee equal to 8.0% of the gross proceeds received in the registered direct
offering and $75,000 for reasonable legal fees and disbursements for the placement agent’s counsel.

On September 17, 2025, in connection with the issuance
of the Promissory Notes, the number of Common Shares exercisable under the January 2024 PIPE Warrants was adjusted in accordance with
the terms of such warrants. As a result of such adjustment, the January 2024 PIPE Warrants are now exercisable for an additional 5,781,250
Common Shares, or Additional Warrant Shares, beyond the 1,126,480 Common Shares exercisable thereunder immediately prior to the adjustment.
On November 14, 2024, 393,790 January 2024 Warrants were exercised for $78,750, and 1,979,110 January 2024 warrants were exercised on
a cashless basis, for which 1,175,328 Common Shares were issued.

In connection with the January 2024 Private Placement,
the selling shareholders named in this prospectus may offer and sell up to an aggregate of 5,781,250 Common Shares issuable upon exercise
of the Additional Warrant Shares underlying the January 2024 PIPE Warrants.

<div align='center'>5</div>

Implications of Being an “Emerging Growth Company” and a Foreign Private Issuer

Emerging Growth Company

We are an “emerging growth company,”
as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the JOBS Act. As such,
we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public